4 research outputs found
Recommended from our members
EVALUATION OF ORGANIC VAPOR RELEASE FROM CEMENT-BASED WASTE FORMS
A cement based waste form was evaluated to determine the rates at which various organics were released during heating caused by the cementitious heat-of-hydration reaction. Saltstone is a cement-based waste form for the disposal of low-level salt solution. Samples were prepared with either Isopar{reg_sign} L, a long straight chained hydrocarbon, or (Cs,K) tetraphenylborate, a solid that, upon heating, decomposes to benzene and other aromatic compounds. The saltstone samples were heated over a range of temperatures. Periodically, sample headspaces were purged and the organic constituents were captured on carbon beds and analyzed. Isopar{reg_sign} L was released from the saltstone in a direct relationship to temperature. An equation was developed to correlate the release rate of Isopar{reg_sign} L from the saltstone to the temperature at which the samples were cured. The release of benzene was more complex and relied on both the decomposition of the tetraphenylborate as well as the transport of the manufactured benzene through the curing saltstone. Additional testing with saltstone prepared with different surface area/volume also was performed
Recommended from our members
ISOPAR L RELEASE FROM SALTSTONE CURED AT 55 C
The decontaminated salt solution waste stream from the Modular Caustic Side Solvent Extraction Unit and the Salt Waste Processing Facility is anticipated to contain entrained extraction solvent. The decontaminated salt solution is scheduled to be processed through Tank 50 into the Saltstone Production Facility. This study, among others, has been undertaken because the solvent concentration in the decontaminated salt solution may cause flammability issues within the Saltstone Disposal Facility that may need to be addressed prior to operation. Previous work at the Savannah River National Laboratory determined the release of Isopar{reg_sign} L from saltstone prepared with a simulated DSS with Isopar{reg_sign} L concentrations ranging from 50 to 200 {micro}g/g in the salt fraction and with test temperatures ranging from ambient to 95 C. The results from the curing of the saltstone showed that the Isopar{reg_sign} L release data can be treated as a percentage of initial concentration in the concentration range studied. The majority of the Isopar{reg_sign} L that was released over the test duration was released in the first few days. The release of Isopar{reg_sign} L begins immediately and the rate of release decreases over time. At higher temperatures the immediate release is larger than at lower temperatures. In this study, saltstone was prepared using a simulated decontaminated salt solution containing Isopar{reg_sign} L concentrations of 50 {micro}L/L (30 {micro}g/g) and 100 {micro}L/L (61 {micro}g/g) and cured at 55 C. The headspace of each sample was purged and the Isopar{reg_sign} L was trapped on a coconut shell carbon tube. The amount of Isopar{reg_sign} L captured was determined using NIOSH Method 1501. The percentage of Isopar{reg_sign} L released after 20 days was 1.4 - 3.7% for saltstone containing 50 {micro}L/L concentration and 2.1 - 4.3% for saltstone containing 100 {micro}L/L concentration. Given the measurement uncertainties in this work there is no clearly discernible relationship between percentage release and initial Isopar{reg_sign} L concentration
Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition
Purpose: Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors.Patients and methods: We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries.Results: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P \u3c .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02).Conclusion: Use of BRAF inhibition results in robust and durable responses in BRAF V600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas